In contrast, international diabetes guidance and consensus reports recommend SGLT2 inhibitors for people with established atherosclerotic CVD, heart failure and CKD,22 irrespective of the additional costs of SGLT2 inhibitors compared to SUs, drawing on evidence from placebo‐controlled RCTs showing improved CVD and kidney disease outcomes when prescribing SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and kidney disorder.